Differences in the management of pediatric and adult onset ulcerative colitis - lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 1, 2014, Pages 1-4

  Ruemmele, Frank M ^a,b   Turner, Dan ^c  

^a Hôtel Dieu Hospital   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Children; Consensus guidelines; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ADJUVANT THERAPY; ADULT DISEASE; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BODY IMAGE; BONE DENSITY; CANCER RISK; CHILD GROWTH; CHILDHOOD DISEASE; COLON RESECTION; CONSENSUS; DECISION MAKING; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; EMOTION; EVIDENCE BASED PRACTICE; FEMALE INFERTILITY; HIGH RISK PATIENT; HUMAN; ILEUM POUCH; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; MEDICAL SOCIETY; MONOTHERAPY; ONSET AGE; PANCOLITIS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTITIS; PUBERTY; QUALITY OF LIFE; REMISSION; RISK BENEFIT ANALYSIS; STEROID THERAPY; ULCERATIVE COLITIS;

CHILDREN; CONSENSUS GUIDELINES; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AGE OF ONSET; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; COLECTOMY; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MESALAMINE; PRACTICE GUIDELINES AS TOPIC;

EID: 84890128936     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.10.006     Document Type: Article

References (26)

1. Levine A., de Bie C.I., Turner D., Cucchiara S., Sladek M., Murphy M.S., et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 2013, 19:370-377.
2. Lev-Tzion R., Turner D. Is pediatric IBD treatment different than in adults?. Minerva Gastroenterol Dietol 2012, 58:137-150.
3. Van Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135:1114-1122.
4. Turner D., Walsh C.M., Benchimol E.I., Mann E.H., Thomas K.E., Chow C., et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008, 57:331-385.
5. Dinesen L.C., Walsh A.J., Protic M.N., Heap G., Cummings F., Warren B.F., et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010, 4:431-437.
6. Turner D., Walsh C.M., Steinhart A.H., Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103-110.
7. Turner D., Griffiths A.M. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011, 17:440-449.
8. Gower-Rousseau C., Dauchet L., Vernier-Massouille G., Tilloy E., Brazier F., Merle V., et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009, 104:2080-2088.
9. Malaty H.M., Mehta S., Abraham B., Garnett E.A., Ferry G.D. The natural course of inflammatory bowel disease-indeterminate from childhood to adulthood: within a 25year period. Clin Exp Gastroenterol 2013, 6:115-121.
10. Markowitz J., Kahn E., Grancher K., Hyams J., Treem W., Daum F. Atypical rectosigmoid histology in children with newly diagnosed ulcerative colitis. Am J Gastroenterol 1993, 88:2034-2037.
11. Rajwal S.R., Puntis J.W., McClean P., Davison S.M., Newell S.J., Sugarman I., et al. Endoscopic rectal sparing in children with untreated ulcerative colitis. J Pediatr Gastroenterol Nutr 2004, 38:66-69.
12. Joo M., Abreu-e-Lima P., Farraye F., Smith T., Swaroop P., Gardner L., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009, 33:854-862.
13. LeLeiko N.S., Lobato D., Hagin S., McQuaid E., Seifer R., Kopel S.J., et al. Rates and predictors of oral medication adherence in pediatric patients with IBD. Inflamm Bowel Dis 2013, 19(4):832-839.
14. Turner D., Levine A., Escher J.C., Griffiths A.M., Russell R.K., Dignass A., et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012, 55(3):340-361.
15. Hanauer S.B., Sandborn W.J., Dallaire C., Archambault A., Yacyshyn B., Yeh C., et al. Delayed-release oral mesalamine 4.8g/day (800mg tablets) compared to 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007, 21(12):827-834.
16. Hanauer S.B., Sandborn W.J., Kornbluth A., Katz S., Safdi M., Woogen S., et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005, 100:2478-2485.
17. Sandborn W.J., Regula J., Feagan B.G., Belousova E., Jojic N., Lukas M., et al. Delayed-release oral mesalamine 4.8g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009, 137(6):1934-1943. (e1-3).
18. Aloi M., D'Arcangelo G., Pofi F., Vassallo F., Rizzo V., Nuti F., et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis 2013, 7:e509-e515. (1).
19. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012, 6:991-1030.
20. Stange E.F., Travis S.P., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
21. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
22. Cochrane Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, CD000478.
23. Hyams J.S., Lerer T., Mack D., et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011, 106:981-987.
24. Cucchiara S., Escher J.C., Hildebrand H., Amil-Dias J., Stronati L., Ruemmele F.M. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?. J Pediatr Gastroenterol Nutr 2009, 48:257-267.
25. Kotlyar D.S., Osterman M.T., Diamond R.H., Porter D., Blonski W.C., Wasik M., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41. (e1).
26. Sokol H., Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009, 58:1427-1436.